Neurocrine Biosciences Reports Mixed Q4
Neurocrine(NBIX) The Motley Fool·2025-02-07 14:08Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.Neurological therapeutics specialist Neurocrine Biosciences (NBIX -0.46%) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted earnings per share (EPS) beat estimates significantly. Overall, the quarter showcased strong performance, particularly from the flagship prescription medication ...